BioTuesdays

Tag - COVID-19

biophytis
Markets

HCW starts Biophytis at buy; PT $15

H.C. Wainwright initiated coverage of Biophytis SA of France (NASDAQ:BPTS) with a “buy” rating and $15 price target. The stock closed at $6.09 on Oct. 22. As a spin-off from Sorbonne University in 2006, Biophytis has...

October 25, 2021
Atea Pharmaceuticals
Markets

SVB Leerink cuts Atea Pharma PT to $20 from $60

SVB Leerink slashed its price target for Atea Pharmaceuticals (NASDAQ:AVIR) to $20 from $60 but maintained its “outperform” rating after the company’s Phase 2 MOONSONG trial in COVID-19 outpatients did not hit its...

October 20, 2021
Neuronetics Logo
Markets

BTIG cuts Neuronetics to neutral

BTIG downgraded Neuronetics (NASDAQ:STIM) to “neutral” and removed its price target, citing disappointing third quarter preliminary revenue and “perplexing fourth quarter guidance.” The stock closed at $6.40 on Oct. 12...

October 13, 2021
Clarus-Therapeutics
Markets

Maxim starts Clarus Therapeutics at buy; PT $13

Maxim Group initiated coverage of Clarus Therapeutics (NASDAQ:CRXT) with a “buy” rating and $13 price target. The stock closed at $5.61 on Sept. 28. Clarus is a commercial-stage company marketing Jatenzo, an oral...

September 29, 2021